Cholinesterase Inhibition Activity and Docking Simulation Study of Coumarin Mannich Base Derivatives

Kiani, Ali; Jalili-baleh, Leili; Abdollahi, Zahra; Nadri, Hamid; Foroumadi, Alireza; Sadat Ebrahimi, Seyed Esmaeil; Khoobi, Mehdi

doi:10.22059/jsciences.2019.256053.1007247

Document Type : Original Paper

Authors

¹ Department of medical Chemistry, school of pharmacy, International campus, Tehran University of Medical Science (IC-TUMS),Tehran, Iran.

² The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417614411, Iran

³ Department of Medicinal Chemistry, Faculty of pharmacy and Pharmaceutical sciences research center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

⁴ Tehran University of Medical Sciences

⁵ Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

⁶ Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran

https://doi.org/10.22059/jsciences.2019.256053.1007247

Abstract

Inhibition of acetylcholinesterase and butyrylcholinesterase (AChE and BuChE) as two major forms of cholinesterases (ChEs) is considered as the common approach for the treatment of Alzheimer's disease (AD). The present study was done to explore the anticholinesterase inhibition property of coumarin Mannich base derivatives. A series of cumarin Manich bases were synthesized (4a-h) through one-pot tri-component reaction in an environmentally friendly condition and evaluated against AChE and BuChE by Ellman's assay. Ligand-protein docking simulation was also performed for the most active compound 4a. Additionally, the criteria of drug likeness of the target compounds was predicted using SwissADME web service. All compounds exhibited weak to moderate inhibitory activity against both AChE and BuChE enzymes. Compound 4a containing p-tolyl piperazin group showed the best activity against AChE (42.4 % at 32 µM), while compound 4g bearing phenylpiperazine moiety was the best BuChE inhibitor (43.9% at 32 µM). Ligand-protein docking simulation also exhibited that the main part of compound 4a in ChE inhibitory activity is amine moiety. Moreover, the prediction of "Lipinski's rule of five" showed that most target compounds can cross the BBB and have properties that would make them likely orally active compounds in humans. This study suggested that the synthesized cumarin Manich bases with some more structural modifications may be considered as a potential compound to target AChE and BuChE.

Keywords

Main Subjects

References

1. Tang H., Zhao H.T., Zhong S.M., Wang Z.Y., Chen Z.F., Liang H. Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. Bioorg. Med. Chem. 22:2257-2261(2012).

2. Querfurth H.W., La Ferla F.M. Mechanism of disease Alzheimer'disease. N. Engl. J. Med. 362:329-344(2010).

3. Pepeu G., Giovannini M.G. Cholinesterase inhibitors and beyond. Curr. AlzheimerRes. 6:86-96(2009) .

4. Mohammadi-Farani A., Abdi N., Moradi A.R., Aliabadi A.R. 2-(2-(4-Benzoylpiperazin-1-yl) ethyl)isoindoline-1,3-dione derivatives: Synthesis, docking and acetylcholinesterase inhibitory evaluation as anti-alzheimer agents. Iran J. Basic Med Sci. 20:59-66(2017).

5. Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol. Res. 50:433-440(2004).

6. Darvesh S., Hopkins D.A., Geula C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci. 4:131-8(2003).

7. Decker M., Krauth F., Lehmann J. Design, synthesis and pharmacological evaluation of hybrid molecules out of quinazolinimines and lipoic acid lead to highly potent and selective butyrylcholinesterase inhibitors with antioxidant properties. J. Bioorg. Med. Chem. 16:4252-61(2008).

8. Eskander M.F., Nagykery N.G., Leung E.Y., Khelghati B., Geula C. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain Res. 1060:144-52(2005).

9. Greig N.H., Utsuki T., Ingram D.K., Wang Y., Pepeu G., Scali C., et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sci. U.S.A 102:17213-8 (2005).

10. Marcelo F., Silva F.V., Goulart M., Justino J., Sinay P., Bleriot Y., Rauter A.P. Synthesis of novel purine nucleosides towards a selective inhibition of human butyrylcholinesterase. Bioorg. Med. Chem. 17:5106-5116(2009).

11. Lane R.M., Potkin S.G., Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int. J. Neuropsychopharmacol. 9:101-24(2006).

12. Alipour M., Khoobi M., Foroumadi A., Nadri H., Moradi A., Sakhteman A., et al. Novel coumarin derivatives bearing N-benzyl pyridinium moiety: Potent and dual binding site acetylcholinesterase inhibitors. Bioorg. Med. Chem. 20:7214-7222(2012).

13. Ghanei-Nasab S., Khoobi M., Hadizadeh F., Marjani A., Moradi A., Nadri H., et al.Synthesis and anticholinesterase activity of coumarin-3-carboxamides bearing tryptamine moiety. Eur. J. Med. Chem. 121:40–46(2016).

14. Razavi S.F., Khoobi M., Nadri H., Sakhteman A., Moradi A., Emami S., et al. Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors. Eur. J. Med. Chem. 64:252–259(2013).

15. Zhou X., Wang X.B., Wang T., Kong L.Y. Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg. Med. Chem. 16:8011-8021(2008).

16. Fallarero A., Oinonen P., Gupta S., Blom P., Galkin A., Mohan C.G., et al. Inhibition of acetylcholinesterase by coumarins: the case of coumarin 106. Pharmacol. Res. 58:215-21(2008).

17. Shen Q., Peng Q., Shao J., Liu X., Huang Z., Pu X., et al. Synthesis and biological evaluation of functionalized coumarins as acetylcholinesterase inhibitors. Eur. J. Med. Chem. 40:1307-15(2005).

18. Soto-Ortega D.D., Murphy B.P., Gonzalez-Velasquez F.J., Wilson K.A., Xie F., Wang Q., et al. Inhibition of amyloid-β aggregation by coumarin analogs can be manipulated by functionalization of the aromatic center. Bioorg. Med. Chem. 19:2596-2602(2011).

19. Piazzi L., Rampa A., Bisi A., Gobbi S., Belluti F., Cavalli A., et al. 3-(4-{[Benzyl(methyl)amino]methyl}phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) Inhibits Both Acetylcholinesterase and Acetylcholinesterase-Induced β-Amyloid Aggregation: A Dual Function Lead for Alzheimer's Disease Therapy. J. Med. Chem. 46:2279-2282(2003).

20. Alipour M., Khoobi M., moradi M., Nadri H., Homayouni Moghadam F., Emami S., et al. Synthesis and anti-cholinesterase activity of new 7-hydroxycoumarin derivatives. Eur. J Med. Chem. 82:536–544(2014).

21. Mannich C. Eine Synthese von β-Ketonic bases. Arch. Pharm. 255: 261276(1917).

22. Montagut-Romans A., Boulven M., Lemaire M., Popowycz F. 3-Methylene-2,4-chromandione in situ trapping : Introducing molecular diversity on 4-hydroxycoumarin. RSC Adv. 6:4540-4544(2016).

23. Asadipour A., Alipour M., Jafari M., Khoobi M., Emami S., Nadri H., et al. Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors. Eur. J. Med. Chem. 70:623-630(2013).

24. Hirbod K., Jalili-baleh L., Nadri H., Sadat Ebrahimi S.E., Moradi A., Pakseresht B., et al. Coumarin derivatives bearing benzoheterocycle moiety: synthesis, cholinesterase inhibitory, and docking simulation study. Iran J. Basic. Med. Sci. 20:631-638(2017).

25. Sreevalli W., Ramachandran G., Madhuri W., Sathiyanarayanan K.I. Green Trends in Mannich Reaction. Mini-Reviews in Org. Chem. 11:97-115(2014).

26. Savel'ev V.L., Artamonova O.S., Troitskaya V.S., et al. Synthesis and study of the properties of 4-substituted 3-aminomethylcoumarins. Chem. Heterocycl. Compd. 18(7):676-679(1982).

27. Robertson D.N., Link K.P. Studies on 4-Hydroxycoumarins. XII. 3-Substituted-aminomethyl-4-hydroxycoumarin Derivatives by the Mannich Reaction. J. Am. Chem. Soc.75:1883-1885(1953).

28. National Center for Biotechnology Information. PubChem Compound Database; CID=54693757, https://pubchem.ncbi.nlm.nih.gov/compound/54693757 (accessed Nov. 18, 2018).

29. National Center for Biotechnology Information. PubChem Compound Database; CID=54687524, https://pubchem.ncbi.nlm.nih.gov/compound/54687524 (accessed Nov. 18, 2018).

30. National Center for Biotechnology Information. PubChem Compound Database; CID=54721006, https://pubchem.ncbi.nlm.nih.gov/compound/54721006 (accessed Nov. 18, 2018).

31. Ellman G.L., Courtney KD., Andres V., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:88-95(1961).

32. Trott O., Olson A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31:455-461(2010).

33. Atul K., Maneesh K.G., Mukesh K. An efficient non-ionic surfactant catalyzed multicomponent synthesis of novel benzylamino coumarin derivative via Mannich type reaction in aqueous media. Tetrahedron Lett. 52:4521-4525(2011).

34. Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 4.5, San Diego: Dassault Systèmes, (2015).

Journal of Sciences, Islamic Republic of Iran

Cholinesterase Inhibition Activity and Docking Simulation Study of Coumarin Mannich Base Derivatives

References

References

21. Mannich C. Eine Synthese von β-Ketonic bases. Arch. Pharm. 255: 261276(1917).

Volume 30, Issue 1
January 2019
Pages 5-12

Cholinesterase Inhibition Activity and Docking Simulation Study of Coumarin Mannich Base Derivatives

References

References

21. Mannich C. Eine Synthese von β-Ketonic bases. Arch. Pharm. 255: 261276(1917).

Volume 30, Issue 1January 2019Pages 5-12

Volume 30, Issue 1
January 2019
Pages 5-12